S. Korea Pharmas Benefit From Scare Over H1N1 Flu As Other Firms Hurt
This article was originally published in PharmAsia News
Executive Summary
South Korea's pharmaceutical industry is benefiting from a growing fear of the H1N1 flu at the same time other industries lose business. When the first two South Korean deaths were attributed to the flu, Green Cross, the nation's only drug maker with H1N1 vaccine production facilities, saw a 15 percent jump in the price of its shares, the limit allowed at the stock market. Green Cross currently is negotiating with the government over the price it is be allowed to charge for the vaccine once it is approved, expected by October. Other drug makers, such as Yuhan, are benefiting from ties to multinational drug makers with flu treatments. (Click here for more